He Tao, Guo Xiangyu, Li Xue, Liao Chunjuan, Wang Xiaorong, He Kun
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610000, China.
J Oncol. 2021 Apr 16;2021:5547911. doi: 10.1155/2021/5547911. eCollection 2021.
Exosomal microRNAs (miRNAs) are considered as potential stable biomarkers in many types of human cancer, but investigations of plasma-derived exosomal miRNAs in oral squamous cell carcinoma (OSCC) are still lacking. The aim of this study is to evaluate the diagnostic and prognostic values of exosomal miR-130a in OSCC patients. Exosomes were isolated from plasma samples which were collected from 184 OSCC patients before surgery and 196 healthy individuals. Primary OSCC and paired adjacent noncancerous tissues were also obtained from 47 OSCC patients. The expression levels of miR-130a were analyzed by quantitative real-time PCR (qRT-PCR). Our results showed that the expression levels of exosomal miR-130a were significantly higher in OSCC patients than those of the healthy controls ( < 0.0001). Also, the expression of miR-130a was also significantly upregulated in OSCC tissues compared with paired adjacent noncancerous tissues ( < 0.0001). A significant positive correlation was found between exosomal miR-130a and tissue miR-130a levels. Receiver operating characteristic (ROC) analyses yielded an AUC value of 0.812 in discriminating OSCC patients from healthy controls. Furthermore, high levels of exosomal miR-130a were associated with the late T-stage (=0.024), advanced TNM stage (=0.003), and poorly differentiated OSCC (=0.013). Patients with high exosomal miR-130a expression had significantly worse 3-year overall survival (OS) and recurrence-free survival (RFS). Multivariate analysis indicated that exosomal miR-130a was an independent prognostic factor for OS (=0.001) and RFS (=0.003). Our results suggest that exosomal miR-130a may serve as a promising diagnostic and prognostic biomarker for OSCC patients.
外泌体微小RNA（miRNA）被认为是多种人类癌症中潜在的稳定生物标志物，但对于口腔鳞状细胞癌（OSCC）患者血浆来源的外泌体miRNA的研究仍较为缺乏。本研究旨在评估外泌体miR-130a在OSCC患者中的诊断和预后价值。从184例OSCC患者术前采集的血浆样本以及196名健康个体的血浆样本中分离出外泌体。还从47例OSCC患者中获取了原发性OSCC组织和配对的相邻非癌组织。通过定量实时PCR（qRT-PCR）分析miR-130a的表达水平。我们的结果显示，OSCC患者中外泌体miR-130a的表达水平显著高于健康对照（<0.0001）。此外，与配对的相邻非癌组织相比，OSCC组织中miR-130a的表达也显著上调（<0.0001）。外泌体miR-130a与组织miR-130a水平之间存在显著正相关。受试者工作特征（ROC）分析显示，区分OSCC患者与健康对照的曲线下面积（AUC）值为0.812。此外，高水平的外泌体miR-130a与晚期T分期（=0.024）、晚期TNM分期（=0.003）以及低分化OSCC（=0.013）相关。外泌体miR-130a表达高的患者3年总生存期（OS）和无复发生存期（RFS）显著更差。多因素分析表明，外泌体miR-130a是OS（=0.001）和RFS（=0.003）的独立预后因素。我们的结果表明，外泌体miR-130a可能是OSCC患者一种有前景的诊断和预后生物标志物。
